CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 25 enrolled
Drug / intervention
dapagliflozin +1 moredrug
Likely dose
dapagliflozin 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04792190
NCT04792190Phase 4Completed
CompareCT.gov

Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation (DAPA-AF) Prospective, Randomized, Multicenter, Placebo-Controlled Trial

University of Rochester·interventional·Posted Mar 10, 2021·Updated Dec 4, 2024

In Brief

A Phase 4 clinical trial evaluating dapagliflozin and Placebo for Atrial Fibrillation. Completed, enrolled 25 participants across 3 sites.

Detailed Summary

This is a multicenter trial to evaluate the impact of treatment with dapagliflozin versus placebo following catheter ablation of atrial fibrillation (AF) on the burden of AF during 6-12 months of follow-up. This prospective, randomized, multicenter, placebo-controlled trial aims to enroll 25 subjects with AF (paroxysmal or persistent) who are scheduled to undergo catheter ablation of patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesUnited States
CollaboratorsAstraZeneca

Timeline

Phase 4CompletedFinished
20222023202420252026
First PostedMar 10, 2021
Enrollment StartJul 27, 2021
Primary CompletionMar 31, 2023
Study CompletionJun 30, 2023
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 5.3 years ago

Interventions

dapagliflozindrug

Subjects will take 1 blinded tablet of study drug (dapagliflozin 10 mg) dosed once daily, for 12 months.

Placebodrug

Subjects will take 1 blinded capsule of placebo drug dosed once daily